AGOAF yields 2000000.00% · JNJ yields 2.13%● Live data
📍 AGOAF pulled ahead of the other in Year 1
Combined, AGOAF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AGOAF + JNJ for your $10,000?
Abengoa, S.A., together with its subsidiaries, provides technology solutions for the energy and water sectors in Spain and rest of Europe, North America, Brazil and rest of South America, Europe, Africa, and the Middle East. It operates through two segments, Engineering and Construction, and Concession-Type Infrastructures. The Engineering and Construction segment offers engineering services, including turnkey projects for thermo-solar plants, solar-gas hybrid plants, conventional generation plants, biofuels plants, and water infrastructures, as well as large-scale desalination plants and transmission lines, and others. It is also involved in the development of solar thermal and water management technologies; and technological business activities, such as hydrogen or the management of energy crops. The Concession-Type Infrastructure segment undertakes take-or-pay contracts or power purchase agreements comprising the operation of electric energy generation plants that include solar, cogeneration, or wind, as well as desalination plants and transmission lines. Abengoa, S.A. was founded in 1941 and is headquartered in Seville, Spain.
Full AGOAF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.